Shattuck Labs

STTK

Market cap $512M

The biotech published its final earnings report and business covering 2025. It posted a slightly narrower-than-expected net loss for the fourth quarter.

AUSTIN, Texas and DURHAM, N.C., March 05, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025 and provided recent business highlights.

AUSTIN, TX and DURHAM, NC, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3-blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that company management will present at and participate in the following upcoming investor conferences: Conference Details TD Cowen 46 th Annual Health Care Conference Format: Corporate presentation and one-on-one meetings Presenter: Taylor Schreiber, M.D., Ph.D., Chief Executive Officer Presentation Date: March 2, 2026 Time: 9:10 AM ET Location: Boston, MA Webcast link: HERE Leerink Partners 2026 Global Health Care Conference Format: One-on-one investor meetings Participant: Taylor Schreiber, M.D.

AUSTIN, TX and DURHAM, NC, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today announced that company management will participate in a fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium, taking place February 12-13, 2026.

An analyst's recommendation upgrade had a major impact on investor sentiment. It's now a buy, according to the pundit.

AUSTIN, TX and DURHAM, NC, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today announced that it has granted inducement equity awards on December 10, 2025 (the “Grant Date”) to a newly-hired non-executive officer.

HC Wainwright upgraded Shattuck Labs Inc. (NASDAQ: STTK) from Neutral to Buy, with a price forecast of $6. The company's lead product candidate, SL-325, is a DR3 antagonist antibody for inflammatory bowel disease (IBD).

AUSTIN, TX and DURHAM, NC, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today announced that Company management will participate in multiple investor conferences in December 2025. Conference Details Conference: Piper Sandler 37th Annual Healthcare Conference Format: Presentation and one-on-one meetings Presenter: Taylor Schreiber, M.D.

–First participants dosed in Phase 1 clinical trial of SL-325 in healthy volunteers – – Closed a private placement of up to $103 million in August 2025 to support advancement of SL-325 – – Appointments of Dan Baker, M.D., and Mona Ashiya, Ph.D.

Shattuck Labs, Inc. (NASDAQ:STTK ) The United European Gastroenterology (UEG) Congress UEG Week 2025 October 8, 2025 10:00 AM EDT Company Participants Taylor Schreiber - Co-Founder, CEO & Director Conference Call Participants Yu Fan - Wedbush Securities Inc., Research Division Marla C Dubinsky David De Vries - TR1X, Inc. David Nierengarten - Wedbush Securities Inc., Research Division Conversation Yu Fan Wedbush Securities Inc., Research Division Okay. Good morning, everybody.